<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00818649</url>
  </required_header>
  <id_info>
    <org_study_id>2008LS044</org_study_id>
    <secondary_id>MT2008-06R</secondary_id>
    <secondary_id>0808M44081</secondary_id>
    <secondary_id>MILLENNIUM-X05269</secondary_id>
    <nct_id>NCT00818649</nct_id>
  </id_info>
  <brief_title>Bortezomib and Vorinostat in Treating Patients With High-Risk Myelodysplastic Syndrome or Acute Myeloid Leukemia</brief_title>
  <official_title>Phase II Trial of Velcade Plus Vorinostat in the Treatment of High Risk MDS and Relapsed/Refractory AML</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Masonic Cancer Center, University of Minnesota</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Millennium Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Masonic Cancer Center, University of Minnesota</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Bortezomib and vorinostat may stop the growth of cancer cells by blocking some of&#xD;
      the enzymes needed for cell growth. Giving bortezomib together with vorinostat may kill more&#xD;
      cancer cells.&#xD;
&#xD;
      PURPOSE: This phase II trial is studying how well giving bortezomib together with vorinostat&#xD;
      works in treating patients with high-risk myelodysplastic syndrome or acute myelogenous&#xD;
      leukemia.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  To determine the clinical response to bortezomib and vorinostat in patients with&#xD;
           high-risk myelodysplastic syndromes or acute myeloid leukemia, as defined by the&#xD;
           International Working Group response criteria.&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  To characterize the quantitative and qualitative toxicities of this regimen in these&#xD;
           patients.&#xD;
&#xD;
        -  To assess the effect of this regimen on natural killer (NK) cell function, in terms of&#xD;
           activating and inhibitory receptor alterations, target cell ligand and HLA class I&#xD;
           modulation, and NK-mediated cell killing.&#xD;
&#xD;
        -  To correlate the above changes with clinical response.&#xD;
&#xD;
      OUTLINE: Patients receive bortezomib subcutaneously (SQ) on days 1, 4, 8, and 11 and oral&#xD;
      vorinostat once daily on days 1-14. Treatment repeats every 21 days for 3 courses in the&#xD;
      absence of disease progression or unacceptable toxicity. Patients who achieve a complete&#xD;
      response, partial response, or hematologic improvement may receive 3 additional courses of&#xD;
      therapy (for a maximum of 6 courses).&#xD;
&#xD;
      Bone marrow and peripheral blood samples are collected at baseline and at the completion of 3&#xD;
      courses of therapy for analysis of target cells (myeloid blasts) (i.e., HLA class I receptor&#xD;
      analysis and natural killer [NK] cell receptor ligand analysis) and analysis of activating NK&#xD;
      cell receptor alterations and NK-mediated cell killing.&#xD;
&#xD;
      After completion of study treatment, patients are followed periodically for up to 1 year.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Met protocol stop rule [i.e., extreme toxicity]&#xD;
  </why_stopped>
  <start_date>January 2009</start_date>
  <completion_date type="Actual">May 2012</completion_date>
  <primary_completion_date type="Actual">May 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Patients by Best Clinical Response</measure>
    <time_frame>At Completion of Course 3 (Day 63)</time_frame>
    <description>Assessed by the International Working Group response criteria: Complete Remission - &lt;5% myeloblasts with normal maturation of all cell lines; Partial Remission - bone marrow blasts decreased by &gt; 50% over pre-treatment but still &gt;5%; and Hematologic Improvement - hemoglobin increase by &gt; 1.5g/dl or decreased transfusions by at least 4/8 week period, platelet absolute increase of &gt;30 X 10^9/L for those starting at &gt;20 X 10^9/L . For those &lt; 20 X 10^9 /L at baseline increase by 100%.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Correlative Laboratory Studies</measure>
    <time_frame>Pre-Study and After 3 Cycles</time_frame>
    <description>Analysis of Natural Killer (NK) Cell Activating and Inhibitory Receptor Alterations, NK Cell Receptor Ligand Alterations, HLA Class I Expression on Target Cells (Myeloid Blasts), and NK-mediated Cell Killing</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlation of Cell Alterations With Clinical Response</measure>
    <time_frame>Pre-Study and After 3 Cycles</time_frame>
    <description>Analysis of Natural Killer (NK) Cell Activating and Inhibitory Receptor Alterations, NK Cell Receptor Ligand Alterations, HLA Class I Expression on Target Cells (Myeloid Blasts), and NK-mediated Cell Killing</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">16</enrollment>
  <condition>Leukemia</condition>
  <condition>Myelodysplastic Syndrome</condition>
  <arm_group>
    <arm_group_label>Velcade + Vorinostat</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>This is a phase II two stage single arm study combining Velcade on days 1, 4, 8, and 11 plus oral Vorinostat days 1-14 of a 21 days cycle. Treatment will continue for a total of 3 treatment cycles.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>bortezomib</intervention_name>
    <description>1.3mg/m^2 via peripheral subcutaneous administration on day 1, 4, 8, 11 of a 21 day cycle</description>
    <arm_group_label>Velcade + Vorinostat</arm_group_label>
    <other_name>Velcade</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>vorinostat</intervention_name>
    <description>400 mg orally (po) every day on days 1-14 of a 21 day cycle</description>
    <arm_group_label>Velcade + Vorinostat</arm_group_label>
    <other_name>suberoylanilide hydroxamic acid (SAHA)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Disease Specific Criteria: Pathologic Diagnosis must be confirmed by University of&#xD;
        Minnesota Hematopathology&#xD;
&#xD;
          -  Myelodysplastic Syndrome (MDS): By IPSS Category: INT-2 or High risk, By WHO&#xD;
             Classification: RAEB-1 or RAEB-2,By cytogenetics: High Risk Cytogenetic Abnormality&#xD;
             Present as defined by the presence Monosomy 7 or complex karyotype. Patients will be&#xD;
             eligible after progressing through standard therapy with either Azacitidine or&#xD;
             Decitabine. Patients with a history of 5q minus syndrome may be eligible after&#xD;
             progressing through treatment with Lenalidomide.&#xD;
&#xD;
          -  Acute Myelogenous Leukemia (AML): Histologic subtypes M0,M1,M2,M4,M5,M6,M7 are&#xD;
             eligible and must meet one of the three criteria below:&#xD;
&#xD;
               -  Refractory Disease/Induction Failure: Failure to achieve initial remission after&#xD;
                  2 lines of induction therapy.&#xD;
&#xD;
               -  Relapsed Disease&#xD;
&#xD;
               -  Newly diagnosed/untreated AML: Patients who are not able to tolerate potentially&#xD;
                  curative conventional induction chemotherapy due to advanced age, end organ&#xD;
                  limitations, or performance status limitation will be eligible.&#xD;
&#xD;
        Additionally, those that refuse conventional induction therapy will be eligible.&#xD;
&#xD;
          -  Patients must have relatively stable bone marrow function during the week prior to&#xD;
             enrollment on the study. White Blood cells (WBC) may be controlled with hydrea. Rapid&#xD;
             WBC doubling not responsive to control with hydrea would indicate unstable bone marrow&#xD;
             function. Ideally WBC should be &lt; 15 X 10^3 /dl at time of study enrollment.&#xD;
&#xD;
          -  Age &gt;18 years&#xD;
&#xD;
          -  Karnofsky performance status &gt; or = 60%&#xD;
&#xD;
          -  Have acceptable organ function as defined within 28 days of enrollment:&#xD;
&#xD;
               -  Hematologic: hemoglobin &gt; 8 g/dL, and platelets &gt; 20k. (Patients may receive&#xD;
                  transfusions of either peripheral red blood cells (PRBC) or platelets to achieve&#xD;
                  these levels)&#xD;
&#xD;
               -  Renal: creatinine &lt; or = 2.0 mg/dL or creatinine clearance &gt; or = 40 ml/min&#xD;
&#xD;
               -  Hepatic: ALT, AST &lt; or = 2.5 x upper limit of normal and total bilirubin &lt; or =&#xD;
                  1.5 X ULN&#xD;
&#xD;
               -  Cardiac: left ventricular ejection fraction &gt; 40% (testing required for all&#xD;
                  patients. For those with prior cardiac history (defined as prior stent or bypass&#xD;
                  surgery) a stress test within 1 month prior to proceeding with the study will be&#xD;
                  required. A cardiology consult will be required for those with prior documented&#xD;
                  cardiac disease or those with any significant EKG/ECHO abnormalities found on&#xD;
                  screening tests.&#xD;
&#xD;
          -  Patients must not have received treatment for their myeloid disorder within 2 weeks of&#xD;
             beginning the trial. Treatments include the use of chemotherapy, hematopoietic growth&#xD;
             factors, and biologic therapy such as monoclonal antibodies. The exception is the use&#xD;
             of hydroxyurea for patients with an elevated WBC. Given the relatively slower expected&#xD;
             clinical response with the study drugs, patients may continue to receive hydroxyurea&#xD;
             through the first cycle of therapy.&#xD;
&#xD;
          -  Must have recovered from clinically significant toxicities from previous therapies.&#xD;
&#xD;
          -  Women of child bearing potential must agree to use adequate contraception (diaphragm,&#xD;
             birth control pills, injections, intrauterine device [IUD], surgical sterilization,&#xD;
             subcutaneous implants, or abstinence, etc.) for the duration of treatment. In&#xD;
             addition, women of childbearing potential must have a negative serum pregnancy test&#xD;
             b-hCG within 72 hours prior to receiving the first dose of therapy. Sexually active&#xD;
             men must agree to use barrier contraceptive for the duration of treatment.&#xD;
&#xD;
          -  Voluntary written informed consent before performance of any study-related procedure&#xD;
             not part of normal medical care, with the understanding that consent may be withdrawn&#xD;
             by the subject at any time without prejudice to future medical care.&#xD;
&#xD;
          -  Treatment History Criteria: Patients who have relapsed after allogeneic stem cell&#xD;
             transplantation are eligible.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnant or lactating. The agents used in this study are known to be teratogenic to a&#xD;
             fetus and there is no information on the excretion of agents into breast milk. All&#xD;
             females of childbearing potential must have a blood test within 72 hours prior to&#xD;
             study drug administration to rule out pregnancy.&#xD;
&#xD;
          -  Grade 2 or greater peripheral neuropathy within 14 days before enrollment&#xD;
&#xD;
          -  Active central nervous system (CNS) disease. Patients with any clinical symptoms of&#xD;
             active CNS disease must have LP with negative cytology.&#xD;
&#xD;
          -  WBC and Peripheral Blast count uncontrolled with hydroxyurea&#xD;
&#xD;
          -  Evidence of QT prolongation with QTc interval greater than 0.5 seconds. QTc&#xD;
             calculation from the EKG machine will be used for this assessment.&#xD;
&#xD;
          -  Clinical evidence of heart failure or history of uncontrolled hypertension. Myocardial&#xD;
             infarction within 6 months prior to enrollment or has New York Heart Association&#xD;
             (NYHA) Class III or IV heart failure, uncontrolled angina, severe uncontrolled&#xD;
             ventricular arrhythmias, or electrocardiographic evidence of acute ischemia or active&#xD;
             conduction system abnormalities. Prior to study entry, any ECG abnormality at&#xD;
             Screening has to be documented by the investigator as not medically relevant.&#xD;
&#xD;
          -  Patients with untreated positive blood cultures or progressive infections as assessed&#xD;
             by radiographic studies&#xD;
&#xD;
          -  Patients with prior use of other histone deacetylase inhibitors (excluding valproic&#xD;
             acid for seizures with a 30 day wash-out period)&#xD;
&#xD;
          -  Known hypersensitivity to Velcade, boron or any of the other agents used in this study&#xD;
&#xD;
          -  Patients with a history of deep vein thrombosis/pulmonary embolism (DVT/PE) that has&#xD;
             not been adequately treated with systemic anticoagulation or that has been recently&#xD;
             diagnosed (within the last 2 months).&#xD;
&#xD;
          -  Serious medical or psychiatric illness likely to interfere with participation in this&#xD;
             clinical study.&#xD;
&#xD;
          -  Active HIV or viral hepatitis infection&#xD;
&#xD;
          -  Other active and potentially life threatening malignancies excluding localized basal&#xD;
             cell or squamous cell skin cancers, cervical carcinoma in situ, superficial bladder&#xD;
             cancer, localized prostate cancer.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Erica Warlick, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Masonic Cancer Center, University of Minnesota</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Masonic Cancer Center, University of Minnesota</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55455</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2017</verification_date>
  <study_first_submitted>January 7, 2009</study_first_submitted>
  <study_first_submitted_qc>January 7, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 8, 2009</study_first_posted>
  <results_first_submitted>January 17, 2013</results_first_submitted>
  <results_first_submitted_qc>January 17, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">February 25, 2013</results_first_posted>
  <last_update_submitted>December 3, 2017</last_update_submitted>
  <last_update_submitted_qc>December 3, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 28, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>de novo myelodysplastic syndromes</keyword>
  <keyword>previously treated myelodysplastic syndromes</keyword>
  <keyword>secondary myelodysplastic syndromes</keyword>
  <keyword>refractory anemia with excess blasts</keyword>
  <keyword>adult acute myeloblastic leukemia with maturation (M2)</keyword>
  <keyword>adult acute myeloblastic leukemia without maturation (M1)</keyword>
  <keyword>adult acute minimally differentiated myeloid leukemia (M0)</keyword>
  <keyword>adult acute myelomonocytic leukemia (M4)</keyword>
  <keyword>adult acute monoblastic leukemia (M5a)</keyword>
  <keyword>adult acute monocytic leukemia (M5b)</keyword>
  <keyword>adult erythroleukemia (M6a)</keyword>
  <keyword>adult pure erythroid leukemia (M6b)</keyword>
  <keyword>adult acute megakaryoblastic leukemia (M7)</keyword>
  <keyword>recurrent adult acute myeloid leukemia</keyword>
  <keyword>untreated adult acute myeloid leukemia</keyword>
  <keyword>adult acute myeloid leukemia with 11q23 (MLL) abnormalities</keyword>
  <keyword>adult acute myeloid leukemia with inv(16)(p13;q22)</keyword>
  <keyword>adult acute myeloid leukemia with t(16;16)(p13;q22)</keyword>
  <keyword>adult acute myeloid leukemia with t(8;21)(q22;q22)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Preleukemia</mesh_term>
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bortezomib</mesh_term>
    <mesh_term>Vorinostat</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Study entry is open to patients regardless of gender or ethnic background.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Velcade + Vorinostat in MDS and AML</title>
          <description>This is a phase II two stage single arm study combining Velcade on days 1, 4, 8, and 11 plus oral Vorinostat days 1-14 of a 21 days cycle. Treatment will continue for a total of 3 treatment cycles.&#xD;
vorinostat : 400 mg orally (po) every day on days 1-14 of a 21 day cycle&#xD;
bortezomib : 1.3mg/m^2 via peripheral subcutaneous administration on day 1, 4, 8, 11 of a 21 day cycle</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Declining performance status</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Unrelated hip fracture-unable to proceed</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Velcade + Vorinostat</title>
          <description>This is a phase II two stage single arm study combining Velcade on days 1, 4, 8, and 11 plus oral Vorinostat days 1-14 of a 21 days cycle. Treatment will continue for a total of 3 treatment cycles.&#xD;
vorinostat : 400 mg orally (po) every day on days 1-14 of a 21 day cycle&#xD;
bortezomib : 1.3mg/m^2 via peripheral subcutaneous administration on day 1, 4, 8, 11 of a 21 day cycle</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="16"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="65.5" lower_limit="47" upper_limit="88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Patients by Best Clinical Response</title>
        <description>Assessed by the International Working Group response criteria: Complete Remission - &lt;5% myeloblasts with normal maturation of all cell lines; Partial Remission - bone marrow blasts decreased by &gt; 50% over pre-treatment but still &gt;5%; and Hematologic Improvement - hemoglobin increase by &gt; 1.5g/dl or decreased transfusions by at least 4/8 week period, platelet absolute increase of &gt;30 X 10^9/L for those starting at &gt;20 X 10^9/L . For those &lt; 20 X 10^9 /L at baseline increase by 100%.</description>
        <time_frame>At Completion of Course 3 (Day 63)</time_frame>
        <population>Evaluable patients are defined as those who completed at least 1 cycle of therapy; 8 had acute myeloid leukemia, 4 had myelodysplastic syndrome.</population>
        <group_list>
          <group group_id="O1">
            <title>Evaluable Patients</title>
            <description>This is a phase II two stage single arm study combining Velcade on days 1, 4, 8, and 11 plus oral Vorinostat days 1-14 of a 21 days cycle. Treatment continued for a total of 3 treatment cycles.&#xD;
vorinostat : 400 mg orally (po) every day on days 1-14 of a 21 day cycle&#xD;
bortezomib : 1.3mg/m^2 via peripheral subcutaneous administration on day 1, 4, 8, 11 of a 21 day cycle</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients by Best Clinical Response</title>
          <description>Assessed by the International Working Group response criteria: Complete Remission - &lt;5% myeloblasts with normal maturation of all cell lines; Partial Remission - bone marrow blasts decreased by &gt; 50% over pre-treatment but still &gt;5%; and Hematologic Improvement - hemoglobin increase by &gt; 1.5g/dl or decreased transfusions by at least 4/8 week period, platelet absolute increase of &gt;30 X 10^9/L for those starting at &gt;20 X 10^9/L . For those &lt; 20 X 10^9 /L at baseline increase by 100%.</description>
          <population>Evaluable patients are defined as those who completed at least 1 cycle of therapy; 8 had acute myeloid leukemia, 4 had myelodysplastic syndrome.</population>
          <units>Patients</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Complete Remission</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Progressive Disease</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Stable Disease</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Correlative Laboratory Studies</title>
        <description>Analysis of Natural Killer (NK) Cell Activating and Inhibitory Receptor Alterations, NK Cell Receptor Ligand Alterations, HLA Class I Expression on Target Cells (Myeloid Blasts), and NK-mediated Cell Killing</description>
        <time_frame>Pre-Study and After 3 Cycles</time_frame>
        <population>Natural Killer cell studies were discontinued after the first 3 patients because the results were not helpful, and thus the secondary outcome measures were not completed.</population>
        <group_list>
          <group group_id="O1">
            <title>Velcade + Vorinostat in MDS and AML</title>
            <description>This is a phase II two stage single arm study combining Velcade on days 1, 4, 8, and 11 plus oral Vorinostat days 1-14 of a 21 days cycle. Treatment will continue for a total of 3 treatment cycles.&#xD;
vorinostat : 400 mg orally (po) every day on days 1-14 of a 21 day cycle&#xD;
bortezomib : 1.3mg/m^2 via peripheral subcutaneous administration on day 1, 4, 8, 11 of a 21 day cycle</description>
          </group>
        </group_list>
        <measure>
          <title>Correlative Laboratory Studies</title>
          <description>Analysis of Natural Killer (NK) Cell Activating and Inhibitory Receptor Alterations, NK Cell Receptor Ligand Alterations, HLA Class I Expression on Target Cells (Myeloid Blasts), and NK-mediated Cell Killing</description>
          <population>Natural Killer cell studies were discontinued after the first 3 patients because the results were not helpful, and thus the secondary outcome measures were not completed.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Correlation of Cell Alterations With Clinical Response</title>
        <description>Analysis of Natural Killer (NK) Cell Activating and Inhibitory Receptor Alterations, NK Cell Receptor Ligand Alterations, HLA Class I Expression on Target Cells (Myeloid Blasts), and NK-mediated Cell Killing</description>
        <time_frame>Pre-Study and After 3 Cycles</time_frame>
        <population>Natural Killer cell studies were discontinued after the first 3 patients because the results were not helpful. So, secondary outcome measures were not completed.</population>
        <group_list>
          <group group_id="O1">
            <title>Velcade + Vorinostat in MDS and AML</title>
            <description>This is a phase II two stage single arm study combining Velcade on days 1, 4, 8, and 11 plus oral Vorinostat days 1-14 of a 21 days cycle. Treatment will continue for a total of 3 treatment cycles.&#xD;
vorinostat : 400 mg orally (po) every day on days 1-14 of a 21 day cycle&#xD;
bortezomib : 1.3mg/m^2 via peripheral subcutaneous administration on day 1, 4, 8, 11 of a 21 day cycle</description>
          </group>
        </group_list>
        <measure>
          <title>Correlation of Cell Alterations With Clinical Response</title>
          <description>Analysis of Natural Killer (NK) Cell Activating and Inhibitory Receptor Alterations, NK Cell Receptor Ligand Alterations, HLA Class I Expression on Target Cells (Myeloid Blasts), and NK-mediated Cell Killing</description>
          <population>Natural Killer cell studies were discontinued after the first 3 patients because the results were not helpful. So, secondary outcome measures were not completed.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <desc>All patients treated on the trial were included in evaluation of toxicity. Toxicities are defined as non-hematologic given the concurrent impact of AML and MDS on cytopenias.</desc>
      <group_list>
        <group group_id="E1">
          <title>Velcade + Vorinostat</title>
          <description>This is a phase II two stage single arm study combining Velcade on days 1, 4, 8, and 11 plus oral Vorinostat days 1-14 of a 21 days cycle. Treatment will continue for a total of 3 treatment cycles.&#xD;
vorinostat : 400 mg orally (po) every day on days 1-14 of a 21 day cycle&#xD;
bortezomib : 1.3mg/m^2 via peripheral subcutaneous administration on day 1, 4, 8, 11 of a 21 day cycle</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTCAE (3.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiac arrest</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Ischemia/Elevated Troponin</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>CTCAE (3.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Febrile neutropenia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Ischemia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>QT prolongation</sub_title>
                <counts group_id="E1" events="9" subjects_affected="6" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Systolic murmur</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Diplopia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Eye pain/blurred vision</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Anorexia</sub_title>
                <counts group_id="E1" events="9" subjects_affected="8" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="11" subjects_affected="7" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Gingival erythema</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Mucositis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Nausea or vomiting</sub_title>
                <counts group_id="E1" events="17" subjects_affected="9" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Rectal/hemorrhoidal pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Small bowel obstruction</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Tongue blister</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="10" subjects_affected="9" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Fever</sub_title>
                <counts group_id="E1" events="6" subjects_affected="3" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Shingles flare</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infection, ANC=.03</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Hip fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Elevated ALT/AST/Alkaline Phosphatase</sub_title>
                <counts group_id="E1" events="10" subjects_affected="2" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Elevated creatinine</sub_title>
                <counts group_id="E1" events="10" subjects_affected="4" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperbilirubinemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Hypoalbuminemia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Hypoglycemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Hypokalemia</sub_title>
                <counts group_id="E1" events="6" subjects_affected="3" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Hyponatremia</sub_title>
                <counts group_id="E1" events="6" subjects_affected="4" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Involuntary movements</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Joint pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Muscle leg pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Muscle weakness</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="5" subjects_affected="3" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Neuropathy</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Pain upon urination</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Dyspnea</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Hypoxia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Nose bleeding</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Pulmonary infection/pneumonia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Fash rash</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Edema</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Erica Warlick, M.D.</name_or_title>
      <organization>Masonic Cancer Center, University of Minnesota</organization>
      <phone>612-625-5467</phone>
      <email>ewarlick@umn.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

